Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Ha Ra, Park, Su Cheol, Choi, Su Jin, Lee, Jae Cheol, Kim, You Cheoul, Han, Chul Ju, Kim, Jin, Yang, Ki Young, Kim, Yeon Joo, Noh, Geum Youb, No, So Hyeon, Jeong, Jae-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379197/
https://www.ncbi.nlm.nih.gov/pubmed/25834802
http://dx.doi.org/10.3350/cmh.2015.21.1.49

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379197/
https://www.ncbi.nlm.nih.gov/pubmed/25834802
http://dx.doi.org/10.3350/cmh.2015.21.1.49

Ejemplares similares